CAR-T cell therapy for new, high-risk mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a type of immunotherapy called CAR-T cells (modified immune cells) for people with untreated, high-risk mantle cell lymphoma. It aims to see if this therapy can help control the disease early on.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of mantle cell lymphoma with certain markers (cyclin D1 or a specific gene change).
- Your lymphoma must be considered 'high risk' (based on a specialized score, growth rate, or a gene mutation called TP53).
- You cannot have had any prior treatment for your lymphoma.
- Your lymphoma must be at stage II, III, or IV (spread beyond one lymph node area).
- You must be between 18 and 75 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
This trial tests a combination of two targeted drugs (sonrotoclax and zanubrutinib) given before your planned CAR-T cell therapy. The goal is to see if this approach can help control the lymphoma while you wait for CAR-T.
This trial tests a new drug called glofitamab for people with mantle cell lymphoma (MCL) whose cancer did not respond or came back after CAR T-cell therapy. Glofitamab is a type of immunotherapy that helps your immune system fight the cancer.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
This trial tests a new CAR-T cell therapy for people with high-risk mantle cell lymphoma that hasn't gotten worse after initial treatment. It aims to see if this targeted immunotherapy can improve outcomes for patients with aggressive disease features.
This trial tests a personalized cancer treatment called CAR-T therapy. It uses your own immune cells, which are modified in a lab to fight your specific type of blood cancer, and then given back to you. The goal is to see if this treatment is safe and feasible when produced locally.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.